Lorrain Daniel S. 4

What Happened Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), sold a total of 4,170 shares in open-market transactions on May 1, 2026 for aggregate proceeds of about $54,694. The filings show two reported lots: 3,870 shares reported at a weighted average price of $13.06 (proceeds $50,542) and 300 shares reported at a weighted average price of $13.84 (proceeds $4,152). These were sales (not purchases), which are commonly routine or pre-planned dispositions.

Key Details

• Transaction date: May 1, 2026 (filed May 1, 2026)
• Reported lots and values:
  • 3,870 shares sold at weighted avg $13.06; proceeds $50,542. Individual trade prices in this lot ranged $12.69–$13.57 (per footnote).
  • 300 shares sold at weighted avg $13.84; proceeds $4,152. Individual trade prices in this lot ranged $13.79–$13.86 (per footnote).
• Total shares sold: 4,170; total proceeds: ~$54,694.
• Footnotes: Transactions were made pursuant to a 10b5-1 trading plan adopted Sept 23, 2025. The filing notes weighted-average prices and offers to provide a per-trade breakdown on request.
• Shares owned after transaction: Not disclosed in the provided excerpt—see the filed Form 4 for post-transaction holdings.
• Timeliness: Filing shows the report and transaction date as May 1, 2026 (no indication of a late filing in the supplied data).

Context Sales executed under a 10b5-1 plan are pre-arranged trades and are generally treated as routine insider dispositions rather than immediate signals of insider sentiment. For retail investors, purchases by insiders tend to be more informative than routine sales; this filing documents a planned sale. For more detail (exact post-sale holdings or per-trade prices), consult the full Form 4 on the SEC EDGAR system.